Reduction in HCV Incidence Among Injection Drug Users Attending Needle and Syringe Programs in Australia

A Linkage Study

Dados Bibliográficos

ID11024601
AutoresJenny Iversen (0000-0002-0062-7300, Jenny Iversen, Handan Wand, John Kaldor, and Lisa Maher are with the Kirby Institute, University of New South Wales, Sydney, Australia. Libby Topp is with Cancer Council NSW, Sydney.), Handan Wand (0000-0002-8279-7652, Jenny Iversen, Handan Wand, John Kaldor, and Lisa Maher are with the Kirby Institute, University of New South Wales, Sydney, Australia. Libby Topp is with Cancer Council NSW, Sydney.), Libby Topp (Jenny Iversen, Handan Wand, John Kaldor, and Lisa Maher are with the Kirby Institute, University of New South Wales, Sydney, Australia. Libby Topp is with Cancer Council NSW, Sydney.), John Kaldor (0000-0002-7639-4355, Jenny Iversen, Handan Wand, John Kaldor, and Lisa Maher are with the Kirby Institute, University of New South Wales, Sydney, Australia. Libby Topp is with Cancer Council NSW, Sydney.), Lisa Maher (0000-0001-6020-6519, Jenny Iversen, Handan Wand, John Kaldor, and Lisa Maher are with the Kirby Institute, University of New South Wales, Sydney, Australia. Libby Topp is with Cancer Council NSW, Sydney.)
Ano2013
Volume103
Fascículo8
Páginas1436-1444
Data de publicação2013-08-01
Peer ReviewedSim
Open AccessNão
TipoARTICLE
PeriódicoAmerican Journal of Public Health (JOURNAL)
Identificadores do periódicoISSN: 0090-0036 • E-ISSN: 1541-0048
EditoraAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.2012.301206
PMID23763399
PMCIDPMC4007859
OpenAlexW1993042950
IdiomaEN
Citações recebidas12
Referências citadas42

Objectives. We examined trends in HCV incident infection among injection drug users (IDUs) attending needle and syringe programs (NSPs) in Australia in 1995 to 2010. Methods. We created a passive retrospective cohort of 724 IDUs who tested negative for HCV antibodies by a simple deterministic method linking partial identifiers to find repeat respondents in annual cross-sectional serosurveillance. Results. We identified 180 HCV seroconversions over the study period, for a pooled incidence density of 17.0 per 100 person-years (95% confidence interval [CI] = 14.68, 19.66). Incidence density declined, from a high of 30.8 per 100 person-years (95% CI = 21.3, 44.6) in 2003 to a low of 4.0 (95% CI = 1.3, 12.3) in 2009. Conclusions. A decline in HCV incidence among Australian IDUs attending NSPs coincided with considerable expansion of harm reduction programs and a likely reduction in the number of IDUs, associated with significant changes in drug markets. Our results demonstrate the capacity of repeat cross-sectional serosurveillance to monitor trends in HCV incidence and provide a platform from which to assess the impact of prevention and treatment interventions

Cohort · Cohort study · Confidence interval · Cross-sectional study · Harm reduction · Human immunodeficiency virus (HIV) · Incidence (geometry) · Pathology · Psychiatry · Psychological intervention · Syringe · Demography · Epidemiology · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · Immunology · Internal Medicine · Medicine · Opioid Use Disorder Treatment